Pulmonary and Systemic Effects of the Phosphodiesterase Inhibitor Dipyridamole in Newborn Lambs with Persistent Pulmonary Hypertension

Nitric oxide (NO) relaxes vascular smooth muscle by increasing the intracellular concentration of cGMP. In the pulmonary circulation, cGMP is inactivated by specific phosphodiesterases (PDE5). Dipyridamole, a clinically approved drug, has inhibitory activity against PDE5 and has been reported to augment the response to inhaled NO in persistent pulmonary hypertension of the newborn (PPHN). We wished to determine whether dipyridamole alone, or in combination with NO, can be used to treat a newborn lamb model of PPHN. In newborn lambs with PPHN, dipyridamole infused at 0.02 mg/kg/min for 45 min alone, or in combination with 5 ppm of inhaled NO for the final 15 min, significantly decreased pulmonary and systemic blood pressure, decreased pulmonary vascular resistance, and increased pulmonary blood flow. There was no significant difference between the pulmonary vascular effects of 5 ppm NO alone compared with the effects of NO combined with dipyridamole. In control lambs, the 45-min infusion of dipyridamole did not change pulmonary pressure whereas systemic pressure decreased by 28 ± 3%. These systemic effects in control lambs persisted 90 min after discontinuing the dipyridamole infusion. Systemic arteries isolated from both control and PPHN lambs were significantly more sensitive to dipyridamole than pulmonary arteries. We conclude that dipyridamole has significant hemodynamic effects in both the pulmonary and systemic circulations of newborn lambs with pulmonary hypertension as well as in the systemic circulation of newborn control lambs. The pronounced effects of dipyridamole on the systemic circulation limits its utility as an adjunct to inhaled NO in the treatment of PPHN.

[1]  W R Clarke,et al.  Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.

[2]  G. Redding,et al.  Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn , 1997 .

[3]  I. Yuhanna,et al.  Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. , 1997, The American journal of physiology.

[4]  A. Stark,et al.  Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. , 1997, The Journal of pediatrics.

[5]  K. Bloch,et al.  Phosphodiesterase 5 (PDE5) Enzyme Activity and Gene Expression Are Altered in Newborn Lambs with Persistent Pulmonary Hypertension. • 1585 , 1997, Pediatric Research.

[6]  N. Finer,et al.  Inhaled nitric oxide enhances oxygenation but not survival in infants with alveolar capillary dysplasia. , 1997, The Journal of pediatrics.

[7]  Jesse D. Roberts,et al.  Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn , 1997 .

[8]  Cook,et al.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. , 1997, The New England journal of medicine.

[9]  W. Carlo,et al.  Inhaled nitric oxide in term infants with hypoxemic respiratory failure. , 1996, The Journal of pediatrics.

[10]  S. Abman,et al.  ELEVATION OF PULMONARY PDE5-SPECIFIC ACTIVITY IN AN EXPERIMENTAL FETAL OVINE PERINATAL PULMONARY HYPERTENSION MODEL. † 1990 , 1996, Pediatric Research.

[11]  J. Skimming,et al.  Effects of Zaprinast and Dissolved Nitric Oxide on the Pulmonary Circulation of Fetal Sheep , 1996, Pediatric Research.

[12]  K. Morris,et al.  Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.

[13]  J. Russell,et al.  The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[14]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[15]  D. Ivy,et al.  Dipyridamole augmentation of response to nitric oxide , 1995, The Lancet.

[16]  D. Ivy,et al.  Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. , 1995, The American journal of physiology.

[17]  K. Stenmark,et al.  Persistent pulmonary hypertension of the newborn. , 1995, American journal of respiratory and critical care medicine.

[18]  W. Hurford,et al.  Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. , 1995, Journal of applied physiology.

[19]  H. Karamanoukian,et al.  Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios. , 1994, Pediatrics.

[20]  H. Magnussen,et al.  Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. , 1994, The American journal of physiology.

[21]  N. Finer,et al.  Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. , 1994, The Journal of pediatrics.

[22]  P. Brown,et al.  Cl- current activation in choroid plexus epithelial cells involves a G protein and protein kinase A. , 1994, The American journal of physiology.

[23]  T. McMahon,et al.  Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.

[24]  S. Soifer,et al.  M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.

[25]  G. Konduri,et al.  Adenosine is a pulmonary vasodilator in newborn lambs. , 1992, The American review of respiratory disease.

[26]  T. Evans,et al.  Chronic hypoxia impairs soluble guanylyl cyclase-mediated pulmonary arterial relaxation in the rat. , 1992, The American journal of physiology.

[27]  W. Thompson.  Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. , 1991, Pharmacology & therapeutics.

[28]  J. Corbin,et al.  Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. , 1990, The Journal of biological chemistry.

[29]  R. Johns,et al.  Endothelium-Dependent Relaxation and Cyclic GMP Accumulation in Rabbit Pulmonary Artery Are Selectively Impaired by Moderate Hypoxia , 1989, Circulation research.

[30]  E. Egan,et al.  The effect of closing the ductus arteriosus on the pulmonary circulation of the fetal sheep. , 1989, Journal of developmental physiology.

[31]  L. Wild,et al.  Ligating the Ductus Arteriosus before birth Remodels the Pulmonary Vasculature of the Lamb , 1989, Pediatric Research.

[32]  J. Oates,et al.  Drug therapy. Dipyrimadole , 1987 .

[33]  C. Lugnier,et al.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. , 1986, Biochemical pharmacology.

[34]  J. Hageman,et al.  Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. , 1984, American journal of diseases of children.

[35]  A. Herman,et al.  Dipyridamole stimulates prostacyclin production in isolated rat aortic tissue. , 1982, Archives internationales de pharmacodynamie et de therapie.

[36]  U. Ryan,et al.  Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. , 1980, The Journal of clinical investigation.

[37]  A. K. Pedersen,et al.  Pharmacokinetics of dipyridamole. , 2009, Acta pharmacologica et toxicologica.

[38]  G. Galanti,et al.  STIMULATION OF PROSTACYCLIN BY DIPYRIDAMOLE , 1979, The Lancet.

[39]  E. K. Weir,et al.  Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated. , 1977, Canadian journal of physiology and pharmacology.

[40]  J. Vogel,et al.  Hypoxic pulmonary hypertension: its modification by dipyridamole. , 1972, The Journal of surgical research.